Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer

  • Wanjun Gu (Contributor)
  • Junchao Shi (Contributor)
  • Hui Liu (Creator)
  • Xudong Zhang (Contributor)
  • Jin J. Zhou (Creator)
  • Musheng Li (Creator)
  • Dandan Zhou (Creator)
  • Rui Li (Creator)
  • Jingzhu Lv (Contributor)
  • Guoxia Wen (Contributor)
  • Shanshan Zhu (Creator)
  • Ting Qi (Creator)
  • Wei Li (Creator)
  • Xiaojing Wang (Creator)
  • Zhaohua Wang (Creator)
  • Hua Zhu (Creator)
  • Changcheng Zhou (Creator)
  • Kenneth S Knox (Creator)
  • Ting Wang (Creator)
  • Qi Chen (Creator)
  • Zhongqing Qian (Contributor)
  • Tong Zhou (University of Nevada, Reno) (Creator)
  • Shi Junchao (Contributor)
  • Li Musheng (Contributor)
  • Zhou Changcheng (Contributor)



Abstract One unmet challenge in lung cancer diagnosis is to accurately differentiate lung cancer from other lung diseases with similar clinical symptoms and radiological features, such as pulmonary tuberculosis (TB). To identify reliable biomarkers for lung cancer screening, we leverage the recently discovered non-canonical small non-coding RNAs (i.e., tRNA-derived small RNAs [tsRNAs], rRNA-derived small RNAs [rsRNAs], and YRNA-derived small RNAs [ysRNAs]) in human peripheral blood mononuclear cells and develop a molecular signature composed of distinct ts/rs/ysRNAs (TRY-RNA). Our TRY-RNA signature precisely discriminates between control, lung cancer, and pulmonary TB subjects in both the discovery and validation cohorts and outperforms microRNA-based biomarkers, which bears the diagnostic potential for lung cancer screening.
Date made available2020

Cite this